Providence, Rhode Island, USA, September 17, 2026
Nabsys, Inc. has announced the publication of research from Augusta University demonstrating the potential of its electronic genome mapping technology for high-resolution analysis of hematologic malignancies. The publication represents the first research paper from Augusta University evaluating Nabsys technology and highlights how electronic genome mapping may provide detailed genomic information from cancer samples. The study investigated the ability of the platform to identify structural genomic alterations, including changes that can be difficult to characterize using conventional genomic approaches. By combining electronic detection with genome mapping, the technology is being explored as a tool for analyzing complex cancer genomes and potentially supporting more comprehensive characterization of disease-associated genomic abnormalities.
Electronic Genome Mapping Provides High-Resolution Analysis
Nabsys’ technology is designed to map DNA at high resolution by detecting individual genomic features electronically. Unlike sequencing methods that primarily determine the order of nucleotide bases, genome mapping focuses on the physical organization of DNA, allowing researchers to examine larger-scale genomic structures and alterations. These can include deletions, insertions, duplications, inversions and other structural variants that may contribute to cancer development and progression. The Augusta University research examined the application of electronic genome mapping to hematologic malignancies, a broad group of cancers affecting blood, bone marrow and the lymphatic system. These diseases can contain complicated genomic changes that influence tumor biology, diagnosis, classification and treatment decisions. A technology capable of detecting structural abnormalities at high resolution could therefore provide researchers with additional information about the genomic architecture of malignant cells.
The publication provides scientific evidence supporting the potential use of electronic genome mapping as a complementary genomic analysis approach. Nabsys said the research demonstrates the ability of its technology to generate detailed genomic maps from cancer specimens, offering another method for investigating structural variation associated with hematologic cancers.
Genomic Structural Variants Offer Cancer Insights
Advertisement
Structural genomic alterations are an important component of cancer biology. Changes involving large sections of DNA can alter gene expression, disrupt regulatory regions or affect genes involved in cell growth and survival. In hematologic malignancies, recurrent chromosomal and genomic abnormalities are often important for understanding disease subtypes and biological behavior. Traditional genomic methods can identify many cancer-associated alterations, but some complex structural variants may require complementary technologies for comprehensive characterization. Nabsys’ electronic genome mapping approach is designed to examine DNA at a larger structural scale while retaining high-resolution information about genomic features.
The Augusta University study is significant because it demonstrates the technology in the context of real cancer research samples rather than solely controlled laboratory materials. Research involving hematologic malignancies can provide a challenging test environment because cancer genomes may contain multiple abnormalities, including complex rearrangements and heterogeneous genomic changes. By generating high-resolution maps of genomic regions, electronic genome mapping could potentially help researchers identify structural abnormalities that warrant further investigation. The technology may also complement sequencing and other cytogenetic approaches by providing information about genome organization that is not always captured through individual sequencing reads.
Potential Applications in Hematologic Malignancies
The publication expands the potential application of Nabsys’ electronic genome mapping platform in oncology research. Hematologic malignancies include leukemias, lymphomas and multiple myeloma, each of which can involve distinct genomic alterations. High-resolution genomic characterization can contribute to research into disease mechanisms, biomarker discovery and molecular classification. The technology could potentially be used alongside established genomic methods to create a more comprehensive picture of cancer genomes. However, the publication demonstrates research potential rather than establishing a validated diagnostic or clinical application. Further studies will be required to determine how electronic genome mapping performs across larger patient populations and how its findings compare with or complement established clinical genomic technologies.
For Nabsys, the Augusta University publication represents an important scientific milestone and adds independent academic research to the growing body of evidence surrounding electronic genome mapping. The company continues to develop its technology for applications in genomics and molecular research, with a focus on detecting complex genomic variation. As precision oncology increasingly depends on detailed understanding of tumor genomes, technologies capable of resolving structural genomic changes may become increasingly valuable in research workflows. The Augusta University study therefore highlights the potential of electronic genome mapping as a complementary approach for high-resolution genomic analysis and provides a foundation for continued investigation of its role in hematologic cancer research.
Source: Nabsys press release
